Figure 5. Dasatinib treatment increases, while Bafetinib treatment lowers, Claudin-2 levels in breast cancer patient derived xenograft explants.

Immunoblot analysis of Claudin-2 expression in GCRC1735 (A) or HCI010 (B) explants derived from triple negative breast cancer human patient derived following treatment with either Dasatinib (30 nM) or Bafetinib (10 μM) inhibitor. As a loading control, total cell lysates were blotted for α-Tubulin.